Optiver Holding
ARQT icon

Optiver Holding’s Arcutis Biotherapeutics ARQT Stock Holding History

Optiver Holding’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Buy
616
+293
+91% +$6.83K ﹤0.01% 1606
2026
Q1 		$7.61K Sell
323
-70
-18% -$1.79K ﹤0.01% 1293
2025
Q4 		$11.4K Sell
393
-236
-38% -$6.04K ﹤0.01% 1119
2025
Q3 		$11.9K Buy
629
+9
+1% +$142 ﹤0.01% 1190
2025
Q2 		$8.69K Buy
620
+252
+68% +$3.53K ﹤0.01% 1043
2025
Q1 		$5.76K Buy
+368
New +$5.18K ﹤0.01% 1059
2024
Q3 		– Sell
-398
Closed -$3.7K – 945
2024
Q2 		$3.7K Buy
+398
New +$3.6K ﹤0.01% 815

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Optiver Holding's ARQT Position: Q2 2026 in Review

Optiver Holding increased its Arcutis Biotherapeutics (ARQT) stake by 91% in Q2 2026, buying an estimated $6.83K and bringing the position to 616 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

Optiver Holding first reported a position in ARQT in Q2 2024 and has held it in 7 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Optiver Holding held 616 shares of Arcutis Biotherapeutics worth $16.2K as of Q2 2026.
  • Optiver Holding bought 293 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.83K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1606 holding.
  • Optiver Holding first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 7 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.